1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. Summary
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Delayed Quote. Delayed Nasdaq Copenhagen - 05/19 10:59:55 am
730.9 DKK   -1.62%
05/16European ADRs Move Higher in Monday Trading
MT
05/16NOVO NORDISK A/S : Share repurchase programme
GL
05/16NOVO NORDISK A/S : Share repurchase programme
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

NOVO NORDISK : Gets a Buy rating from Bernstein

01/24/2022 | 03:54am EDT

Analyst Wimal Kapadia from Bernstein research considers the stock attractive and recommends it with a Buy rating. The target price remains unchanged at DKK 750.


© MarketScreener with dpa-AFX Analyser 2022
All news about NOVO NORDISK A/S
05/16European ADRs Move Higher in Monday Trading
MT
05/16NOVO NORDISK A/S : Share repurchase programme
GL
05/16NOVO NORDISK A/S : Share repurchase programme
GL
05/13U.S. FDA approves Eli Lilly's treatment for type 2 diabetes
RE
05/12NOVO NORDISK : Barclays gives a Buy rating
MD
05/11NOVO NORDISK A/S : Trading in Novo Nordisk shares by board members, executives and associa..
GL
05/11NOVO NORDISK : Deutsche Bank keeps its Buy rating
MD
05/10Novo Nordisk Starts Research Collaboration With Flagship Pioneering
MT
05/09Novo Nordisk - major shareholder announcement
AQ
05/06NOVO NORDISK A/S :
GL
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Financials
Sales 2022 166 B 23 615 M 23 615 M
Net income 2022 52 794 M 7 512 M 7 512 M
Net cash 2022 4 087 M 582 M 582 M
P/E ratio 2022 31,2x
Yield 2022 1,57%
Capitalization 1 660 B 236 B 236 B
EV / Sales 2022 9,98x
EV / Sales 2023 8,81x
Nbr of Employees 49 295
Free-Float 69,6%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | MarketScreener
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 730,90 DKK
Average target price 791,88 DKK
Spread / Average Target 8,34%
EPS Revisions
Managers and Directors
Lars Fruergaard Jørgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Henrik Ehlers Wulff Senior Vice President-Diabetes API
Stephen Gough Global Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S1.07%236 239
JOHNSON & JOHNSON2.59%461 811
PFIZER, INC.-14.23%282 789
ABBVIE INC.12.05%269 361
ELI LILLY AND COMPANY3.64%265 718
ROCHE HOLDING AG-15.26%264 329